Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glasdegib combinations in relapsed AML post-transplant
NCT04655391Phase 1Withdrawn
- Sponsor
- City of Hope
- Start
- Jun 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of glasdegib in acute myeloid leukemia (AML) (5 arms), sponsored by City of Hope. Primary endpoints: Ability to obtain a molecular diagnosis at 30 days, Ability to make a treatment arm assignment at 30 days and 1 more. Planned start Jun 2022; status: withdrawn.
02
Drugs
glasdegib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04655391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04655391.